Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Volume 45(4);  2024 Apr

Articles from this journal are generally available in PMC after a 12-month delay (embargo); however, the delay may vary at the discretion of the publisher.

Articles

Sigma-1 receptor activation mediates the sustained antidepressant effect of ketamine in mice via increasing BDNF levels
Hui Ma, Jin-feng Li, Xin Qiao, Yue Zhang, Xiao-juan Hou, Hai-xia Chang, Hong-lei Chen, Yong Zhang, Yun-feng Li
Acta Pharmacol Sin. 2024 Apr; 45(4): 704–713. Published online 2023 Dec 14. doi: 10.1038/s41401-023-01201-8
PMCID:
PMC10943013
O-GlcNAcylation mediates H2O2-induced apoptosis through regulation of STAT3 and FOXO1
Chen-chun Zhang, Yuan Li, Chang-you Jiang, Qiu-min Le, Xing Liu, Lan Ma, Fei-fei Wang
Acta Pharmacol Sin. 2024 Apr; 45(4): 714–727. Published online 2024 Jan 8. doi: 10.1038/s41401-023-01218-z
PMCID:
PMC10943090
Chemokine CCL2 promotes cardiac regeneration and repair in myocardial infarction mice via activation of the JNK/STAT3 axis
Wei Wang, Xiao-kang Chen, Lu Zhou, Feng Wang, Yan-ji He, Bing-jun Lu, Ze-gang Hu, Zhu-xin Li, Xue-wei Xia, Wei Eric Wang, Chun-yu Zeng, Liang-peng Li
Acta Pharmacol Sin. 2024 Apr; 45(4): 728–737. Published online 2023 Dec 12. doi: 10.1038/s41401-023-01198-0
PMCID:
PMC10943228
Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition
Qian Wu, Wan-jie Liu, Xin-yu Ma, Ji-shuo Chang, Xiao-ya Zhao, Ying-hua Liu, Xi-yong Yu
Acta Pharmacol Sin. 2024 Apr; 45(4): 738–750. Published online 2023 Dec 14. doi: 10.1038/s41401-023-01191-7
PMCID:
PMC10943222
Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation
Xiao-xue Li, Zheng-dong Chen, Xue-jiao Sun, Yi-qing Yang, Hong Jin, Nai-feng Liu
Acta Pharmacol Sin. 2024 Apr; 45(4): 751–764. Published online 2024 Jan 3. doi: 10.1038/s41401-023-01217-0
PMCID:
PMC10943241
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells
Meng-yang Wang, Tian-xiang Yu, Qin-yan Wang, Xue Han, Xiang Hu, Shi-ju Ye, Xiao-hong Long, Yi Wang, Hong Zhu, Wu Luo, Guang Liang
Acta Pharmacol Sin. 2024 Apr; 45(4): 765–776. Published online 2023 Dec 18. doi: 10.1038/s41401-023-01192-6
PMCID:
PMC10943066
DsbA-L ameliorates renal aging and renal fibrosis by maintaining mitochondrial homeostasis
Ming Yang, Yan Liu, Shi-lu Luo, Chong-bin Liu, Na Jiang, Chen-rui Li, Hao Zhao, Ya-chun Han, Wei Chen, Li Li, Lin Sun
Acta Pharmacol Sin. 2024 Apr; 45(4): 777–789. Published online 2024 Jan 10. doi: 10.1038/s41401-023-01216-1
PMCID:
PMC10943083
Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis
Zong-bao Ding, Yan Chen, Yu-rong Zheng, Yi-yuan Wang, Wen-de Deng, Jie-huang Zheng, Qin Yang, Zi-ye Chen, Li-hong Li, Hui Jiang, Xiao-juan Li
Acta Pharmacol Sin. 2024 Apr; 45(4): 790–802. Published online 2024 Jan 8. doi: 10.1038/s41401-023-01209-0
PMCID:
PMC10943029
Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice
Jing-jing Shao, Wei-feng Li, Jin-feng Sun, Zai-shou Zhuang, Ju-lian Min, Xiao-hong Long, Gao-jun Wu, Hao-wen Xu, Guang Liang
Acta Pharmacol Sin. 2024 Apr; 45(4): 803–814. Published online 2024 Jan 3. doi: 10.1038/s41401-023-01212-5
PMCID:
PMC10943196
Lonicerin promotes wound healing in diabetic rats by enhancing blood vessel regeneration through Sirt1-mediated autophagy
Zhen Lin, Lu-yao Li, Lu Chen, Chen Jin, Yue Li, Lan Yang, Chang-zhou Li, Cai-yu Qi, Yu-yang Gan, Jia-rui Zhang, Piao Wang, Li-bin Ni, Gao-feng Wang
Acta Pharmacol Sin. 2024 Apr; 45(4): 815–830. Published online 2023 Dec 8. doi: 10.1038/s41401-023-01193-5
PMCID:
PMC10943091
E3 ubiquitin ligase NEDD4L inhibits epithelial-mesenchymal transition by suppressing the β-catenin/HIF-1α positive feedback loop in chronic rhinosinusitis with nasal polyps
Si-yuan Chen, Pei-qiang Liu, Dan-xue Qin, Hao Lv, Hui-qin Zhou, Yu Xu
Acta Pharmacol Sin. 2024 Apr; 45(4): 831–843. Published online 2023 Dec 5. doi: 10.1038/s41401-023-01190-8
PMCID:
PMC10943232
SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer
Hai-di Chen, Zeng Ye, Hai-feng Hu, Gui-xiong Fan, Yu-heng Hu, Zheng Li, Bo-rui Li, Shun-rong Ji, Chen-jie Zhou, Xiao-wu Xu, Xian-jun Yu, Yi Qin
Acta Pharmacol Sin. 2024 Apr; 45(4): 844–856. Published online 2023 Dec 6. doi: 10.1038/s41401-023-01199-z
PMCID:
PMC10943101
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
Wen-jing Li, Cheng-ying Xie, Xi Zhu, Jiao Tang, Lei Wang, Li-guang Lou
Acta Pharmacol Sin. 2024 Apr; 45(4): 857–866. Published online 2024 Jan 10. doi: 10.1038/s41401-023-01221-4
PMCID:
PMC10942974
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
Ting-ting Lin, Wei Xiong, Gui-hua Chen, Yang He, Li Long, Xin-fu Gao, Jia-lin Zhou, Wen-wen Lv, Yong-zhuo Huang
Acta Pharmacol Sin. 2024 Apr; 45(4): 867–878. Published online 2023 Dec 19. doi: 10.1038/s41401-023-01205-4
PMCID:
PMC10943229

Review Articles

Nucleic acid and protein methylation modification in renal diseases
Juan Jin, Xue-mei Liu, Wei Shao, Xiao-ming Meng
Acta Pharmacol Sin. 2024 Apr; 45(4): 661–673. Published online 2023 Dec 15. doi: 10.1038/s41401-023-01203-6
PMCID:
PMC10943093
Autoimmune diseases: targets, biology, and drug discovery
Shu-jie Li, Yan-li Wu, Juan-hua Chen, Shi-yi Shen, Jia Duan, H. Eric Xu
Acta Pharmacol Sin. 2024 Apr; 45(4): 674–685. Published online 2023 Dec 14. doi: 10.1038/s41401-023-01207-2
PMCID:
PMC10943205
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Yi Chen, Qiu-pei Liu, Hua Xie, Jian Ding
Acta Pharmacol Sin. 2024 Apr; 45(4): 686–703. Published online 2023 Dec 4. doi: 10.1038/s41401-023-01194-4
PMCID:
PMC10943119

Articles from Acta Pharmacologica Sinica are provided here courtesy of Nature Publishing Group